Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 110.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 148.50
  • 52 Week Low: 101.00
  • Currency: UK Pounds
  • Shares Issued: 106.23m
  • Volume: 56,952
  • Market Cap: £116.85m
  • RiskGrade: 258

Cello hikes dividend after fruitful second half

Date: Wednesday 13 Mar 2013

LONDON (ShareCast) - Marketing firm Cello Group said after a challenging first half, it recovered strongly in the second half, as it looks forward to further progress in the current year.

Gross profit rose 7.2% to £65.1m for the year to December 31st 2012 with like-for-like gross profit up 2.6% despite the challenging first half.

Headline operating profit fell to £7.7m from £7.8m while headline pre-tax profits slipped to £7.0m from £7.1m.

Chief executive Mark Scott said: "2012 has seen the group continue to grow its pharmaceutical expertise in the UK and overseas markets. The recent acquisition of Mash Health, combined with centralised new business activity and further organic investment, will continue this progress into 2013."

"We are confident that both these factors will combine to deliver a successful 2013 performance and as an indicator of that confidence we have raised the dividend by 16.3%, the sixth successive year of dividend growth."

Cello said momentum is continuing in the early stages of the current year.

The group has proposed a full year dividend of 2.0p per share compared to 1.72p last time.


CJ

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 110.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 148.50
52 Week Low 101.00
Volume 56,952
Shares Issued 106.23m
Market Cap £116.85m
RiskGrade 258

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.69% below the market average64.69% below the market average64.69% below the market average64.69% below the market average64.69% below the market average
83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average
Price Trend
21.22% above the market average21.22% above the market average21.22% above the market average21.22% above the market average21.22% above the market average
12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average
Income
26.26% below the market average26.26% below the market average26.26% below the market average26.26% below the market average26.26% below the market average
86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average86.67% above the sector average
Growth
39.24% below the market average39.24% below the market average39.24% below the market average39.24% below the market average39.24% below the market average
38.89% below the sector average38.89% below the sector average38.89% below the sector average38.89% below the sector average38.89% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 09-Apr-2020

Time Volume / Share Price
16:31 25,000 @ 110.00p
16:06 25,000 @ 110.00p
15:57 608 @ 111.64p
15:45 1,897 @ 112.00p
14:39 4,450 @ 109.06p

Cello Health Key Personnel

CEO Mark Scott

Top of Page